This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
We are skeptical of the benefits of botulinum toxin type A (BoNT/A) in treating neuropathic pain.1 We also believe that Apfel's2 accompanying editorial was too positive regarding this study involving only 18 patients.
Sleep problems and quality of life scores have nothing in common with results of the visual analog scale (VAS) and these are our patients' major concerns. In addition, the pattern of injections is not related to the areas where our patients complain about pain, including the toes and balls of the feet. Furthermore, data have shown that injection sites followed the pain.3,4
The study would have benefited by having independent funding rather than relying on the largess of Allergan for the BoNT/A. BoNT/A has proven indications, but the drive to expand them is industry-driven and is reminiscent of the marketing strategy of …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
